ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib

Wang, Zongwen; Zhu, Qiankun; Li, Xiaodong; Ren, Xiaohang; Li, Jingtao; Zhang, Yao; Zeng, Shicong; Xu, Lishan; Dong, Xiaoqun*; Zhai, Bo*哈尔滨医科大学
American Journal of Cancer Research2022
7被引5阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death attributed to high fre-quency of metastasis and multiple drug resistance. We aim to examine the underlying molecular mechanism and to seek potential strategies to reverse primary/acquired resistance to regorafenib. Topoisomerase II alpha (TOP2A) is criti-cal for tumorigenesis and carcinogenesis. Clinically, high-TOP2A expression was correlated to shorter overall survival (OS) of patients, but its role in drug resistance of HCC remains unknown. Here, we screened the expression profiling of TOP2A in HCC and identified TOP2A as an upregulated gene involved in the resistance to regorafenib. Sustained exposure of HCC cells to regorafenib could upregulate the expression of TOP2A. Silencing TOP2A enhanced HCC cells' sensitivity to regorafenib. TOP2A inhibition by doxorubicin or epirubicin synergized with regorafenib to sup-press the growth of sorafenib-resistant HCC tumors that possessed the sorafenib-resistant features both in vitro and in vivo. Thus, targeting TOP2A may be a promising therapeutic strategy to alleviate resistance to regorafenib and thus improving the efficacy of HCC treatment.

学科与关键词

关键词
TOP2Aregorafenibhepatocellular carcinoma
相关
加载中…
  • Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
  • Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinoma
    Shi, Chuan-Jian; Lv, Min-Yi; Deng, Li-Qiang; Zeng, Wei-Qiang; Fu, Wei-Ming*; Zhang, Jin-Fang*Cell Biology and Toxicology, 2023, 39(4): 1735-1752.被引 1
  • Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
    Luo, Jialiang; Li, Lei; Zhu, Zhengyumeng; Chang, Bo; Deng, Fan; Wang, Di; Lu, Xiao; Zuo, Daming; Chen, Qingyun*; Zhou, Jia*Biomedicine and Pharmacotherapy, 2022, 154: 113602.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
American Journal of Cancer Research
发表日期
2022
卷期
第 12 卷, 第 9 期
页码
4343-+
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Spark Research Fund of The Fourth Affiliated Hospital of Harbin Medical University [HYDSYXH201904]

作者

  • W

    Wang, Zongwen (第一作者)

    harbin med univ

  • Z

    Zhu, Qiankun

    harbin med univ

查看全部 10 位作者收起作者
  • L

    Li, Xiaodong

    harbin med univ

  • R

    Ren, Xiaohang

    harbin med univ

  • L

    Li, Jingtao

    harbin med univ

  • Z

    Zhang, Yao

    harbin med univ

  • Z

    Zeng, Shicong

    harbin med univ

  • X

    Xu, Lishan

    harbin med univ

  • D

    Dong, Xiaoqun (通讯)

  • Z

    Zhai, Bo (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417